Cerevance reported that solengepras—an experimental, add-on Parkinson’s pill not designed to act directly on dopamine—reduced daily “off time” in a Phase 3 trial. The company said it will engage regulators about a potential approval, positioning the therapy as a mechanistic alternative that may avoid dyskinesia-linked limitations seen with standard dopaminergic regimens. In cancer, separate trial-readouts point to continued refinement of how immunotherapy and targeted approaches are sequenced and compared. An expert-elicitation effort also highlighted the difficulty of making clean cross-trial comparisons for CAR-T therapies, listing prognostic and modifier variables that should be adjusted. Overall, the thread running through the updates is differentiation: therapies are being judged not only on mean efficacy, but on symptom timing, tolerability, and trial-to-trial interpretability—factors that can determine regulatory pathways and future prescribing behavior.